 By David Bautz, PhD NASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT Business Update Topline Results from Phase 3 Trial of M-001 Expected by End of 2020 BiondVax Pharmaceuticals, Ltd. NASDAQ:BVXV is a biopharmaceutical company developing a universal influenza vaccine M-001 designed to protect individuals from all strains of influenza. The companys strategy for commercializing M-001 involves 